» Articles » PMID: 32903400

Azole-Resistant Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR/L98H

Abstract

Azole-resistant (azole-R) is an increasing challenge worldwide. Patients with cystic fibrosis (CF) are at risk of colonization and disease due to a favorable lung environment for microorganisms. We performed a nationwide study in 2018 of azole-non-susceptible in CF patients and compared with data from two prior studies. All airway samples with mold isolates from patients monitored at the two CF centers in Denmark (RH, Jan-Sept and AUH, Jan-Jun) were included. Classical species identification (morphology and thermo-tolerance) was performed and MALDI-TOF/β-tubulin sequencing was performed if needed. Susceptibility was determined using EUCAST E.Def 10.1, and E.Def 9.3.2. sequencing and STR genotyping were performed for azole-non-susceptible isolates and relevant sequential isolates. In total, 340 mold isolates from 159 CF patients were obtained. The most frequent species were (266/340, 78.2%) and (26/340, 7.6%). Azole-R was cultured from 7.3% (10/137) of patients, including 9.5% (9/95) of patients at RH and 2.4% at AUH (1/42), respectively. In a 10-year perspective, azole-non-susceptibility increased numerically among patients at RH (10.5% in 2018 vs 4.5% in 2007-2009). Cyp51A resistance mechanisms were found in nine azole-R from eight CF patients. Five were of environmental origin (TR/L98H), three were human medicine-driven (two M220K and one M220R), and one was novel (TR /L98H) and found in a patient who also harbored a TR/L98H isolate. STR genotyping identified 27 unique genotypes among 45 isolates and ≥2 genotypes in 8 of 12 patients. This included one patient carrying two unique TR/L98H isolates, a rare phenomenon. Genotyping of sequential TR /L98H and TR/L98H isolates from the same patient showed only minor differences in 1/9 markers. Finally, azole-R was found in three patients including two with Cyp51A alterations (M217I and G51A, respectively). Azole-R is increasing among CF patients in Denmark with the environmentally associated resistance TR/L98H mechanism being dominant. Mixed infections (wildtype/non-wildtype and several non-wildtypes) and a case of potential additional tandem repeat acquisition were found. However, similar genotypes were identified from another patient (and outside this study), potentially suggesting a predominant TR/L98H clone in DK. These findings suggest an increasing prevalence and complexity of azole resistance in .

Citing Articles

Comprehensive Review of Environmental Surveillance for Azole-Resistant : A Practical Roadmap for Hospital Clinicians and Infection Control Teams.

Tashiro M, Nakano Y, Shirahige T, Kakiuchi S, Fujita A, Tanaka T J Fungi (Basel). 2025; 11(2).

PMID: 39997390 PMC: 11856238. DOI: 10.3390/jof11020096.


Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant spp.

EFSA J. 2025; 23(1):e9200.

PMID: 39886075 PMC: 11780318. DOI: 10.2903/j.efsa.2025.9200.


Unveiling environmental transmission risks: comparative analysis of azole resistance in clinical and environmental isolates from Yunnan, China.

Gong J, Huang J, Liu Y, Zhang Y, Gao Y Microbiol Spectr. 2024; :e0159424.

PMID: 39470286 PMC: 11619395. DOI: 10.1128/spectrum.01594-24.


Fungal lung disease.

Jaggi T, Agarwal R, Tiew P, Shah A, Lydon E, Hage C Eur Respir J. 2024; 64(5).

PMID: 39362667 PMC: 11602666. DOI: 10.1183/13993003.00803-2024.


Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.

Saiman L, Waters V, LiPuma J, Hoffman L, Alby K, Zhang S Clin Microbiol Rev. 2024; 37(3):e0021521.

PMID: 39158301 PMC: 11391703. DOI: 10.1128/cmr.00215-21.


References
1.
Stevens D, Moss R, Hernandez C, Clemons K, Martinez M . Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. Antimicrob Agents Chemother. 2016; 60(4):2180-4. PMC: 4808157. DOI: 10.1128/AAC.02649-15. View

2.
Williams C, Ranjendran R, Ramage G . Pathogenesis of Fungal Infections in Cystic Fibrosis. Curr Fungal Infect Rep. 2016; 10(4):163-169. PMC: 5155017. DOI: 10.1007/s12281-016-0268-z. View

3.
Lestrade P, Meis J, Melchers W, Verweij P . Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clin Microbiol Infect. 2018; 25(7):799-806. DOI: 10.1016/j.cmi.2018.11.027. View

4.
Morio F, Aubin G, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D . High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother. 2012; 67(8):1870-3. DOI: 10.1093/jac/dks160. View

5.
Imbert S, Normand A, Gabriel F, Cassaing S, Bonnal C, Costa D . Multi-centric evaluation of the online MSI platform for the identification of cryptic and rare species of Aspergillus by MALDI-TOF. Med Mycol. 2019; 57(8):962-968. DOI: 10.1093/mmy/myz004. View